Futibatinib (Lytgobi) is a rare alkyne-containing, irreversible FGFR1-4 inhibitor that received accelerated approval from the FDA in September 2022. Structurally distinct from other approved FGFR2/3 inhibitors, futibatinib treats a range of FGFR-aberrant tumors, including those with fusions or TKI-resistant mutants like the V565I/L gatekeeper mutation.
This Premium report reviews:
- the role of FGFR mutations in oncogenesis and drug resistance
- differences between approved and emerging FGFR inhibitors
- human data on futibatinib, including PK and efficacy
See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.
request a trial
Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.
Interested in learning more? Submit this form to request a trial.
